acorda therapeutics inc  acorda announces departure of chief medical officer cmo company appoints burkhard blank md as interim cmo toggle navigation menu privacy policy terms of use site map contact us  back investor news acorda announces departure of chief medical officer cmo company appoints burkhard blank md as interim cmo  download this press release pdf ardsley nybusiness wire acorda therapeutics inc nasdaqacor today announced that chief medical officer cmo enrique carrazana md is leaving the company effective january   burkhard blank md who has served as cmo for several biopharmaceutical companies including boehringer ingelheim will assume the responsibilities of cmo on an interim basis dr carrazana is expected to serve as a consultant to the company following his departure “we thank enrique for his significant contributions to acorda during the last four years as we grew from having a single product to a robust pipeline of six clinicalstage compounds including three phase  programs” said ron cohen md president and ceo of acorda therapeutics “we anticipate that burkhard who has led multiple clinical programs successfully to fda approval will contribute substantially to acorda’s programs going forward dr blank has more than  years of industry experience holding senior leadership positions with responsibility for managing international clinical trial programs as well as heading regulatory affairs statistics drug safety and related departments as cmo of boehringer ingelheim pharmaceuticals inc dr blank oversaw the submission of five new drug applications ndas and had direct responsibility for all aspects of presenting at two us food and drug administration fda advisory committee meetings all five ndas received fda approval dr blank has also served as a strategic advisor to several biotechnology companies leading the submission process for multiple investigational drug applications inds successfully developing protocols for clinical trial programs and overseeing communications with regulatory agencies dr blank is a boardcertified internist and received his medical degree from universitaet marburg germany prior to his appointment as interim cmo dr blank served as a consultant to the company’s commercial and business development departments about acorda therapeutics founded in  acorda therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders acorda markets three fdaapproved therapies including ampyra® dalfampridine extended release tablets  mg the company has one of the leading pipelines in the industry of novel neurological therapies acorda is currently developing a number of clinical and preclinical stage therapies this pipeline addresses a range of disorders including poststroke walking deficits parkinson’s disease epilepsy heart failure ms and spinal cord injury for more information please visit the company’s website at wwwacordacom forwardlooking statements this press release includes forwardlooking statements within the meaning of the private securities litigation reform act of  all statements other than statements of historical facts regarding managements expectations beliefs goals plans or prospects should be considered forwardlooking these statements are subject to risks and uncertainties that could cause actual results to differ materially including the ability to realize the benefits anticipated from the civitas transaction and to successfully integrate civitas operations into our operations our ability to successfully market and sell ampyra in the us third party payers including governmental agencies may not reimburse for the use of ampyra or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions the risk of unfavorable results from future studies of ampyra or from our other research and development programs including cvt plumiaz diazepam nasal spray or any other acquired or inlicensed programs we may not be able to complete development of obtain regulatory approval for or successfully market cvt plumiaz or any other products under development we may need to raise additional funds to finance our expanded operations and may not be able to do so on acceptable terms the occurrence of adverse safety events with our products delays in obtaining or failure to obtain regulatory approval of or to successfully market fampyra outside of the us and our dependence on our collaboration partner biogen international gmbh in connection therewith competition failure to protect our intellectual property to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products and failure to comply with regulatory requirements could result in adverse action by regulatory agencies these and other risks are described in greater detail in acorda therapeutics filings with the securities and exchange commission acorda may not actually achieve the goals or plans described in its forwardlooking statements and investors should not place undue reliance on these statements forwardlooking statements made in this release are made only as of the date hereof and acorda disclaims any intent or obligation to update any forwardlooking statements as a result of developments occurring after the date of this release view source version on businesswirecom httpwwwbusinesswirecomnewshomeen source acorda therapeutics acorda therapeuticsjeff macdonald jmacdonaldacordacom stock quote acor common stock     volume  more july   quick links view our investor kit meet our leadership team board of directors contact us pipeline sec filings email alerts unsubscribe from email alerts email address  mailing lists  news releases alert sec alert events alert calendar alert   enter the code shown above  text size normal larger largest print about acorda message from our ceo company leadership management team board of directors partnering with acorda grant program scientific award contact us compliance for patients focus on therapies in the community resources policy on access to unapproved medicines products  research pipeline arcus® technology products ampyra® dalfampridine zanaflex capsules® tizanidine hcl qutenza® capsaicin  patch clinical trials research  development cvt tozadenant syn syn btt timolumab cvt rhigm investors corporate governance stock information investors events press releases financial information quarterly reports annual reports sec filings analysts investor resources investor kit email alerts faqs ir contact news  events in the news awards press releases company events social media careers working at acorda meet our employees benefits job openings application home  privacy policy  terms of use  site map  contact us  copyright  powered by q inc burkhard blank acorda therapeutics inc profile  biography  bloomberg feedback burkhard blank chief medical officer acorda therapeutics inc career history chief medical officer acorda therapeutics inc present interim chief medical officer acorda therapeutics inc  senior vpchief medical ofcr altus pharmaceuticals inc  senior vpmedicine  reg afr altus pharmaceuticals inc  senior vpm  d reg affairs boehringer ingelheim gmbh  chief medical officer herantis pharma plc unknown exec vpchief medical officer altus pharmaceuticals inc former chief executive officer laurantis pharma oy former chief medical officer boehringer ingelheim pharmaceuticals former show more website wwwacordacom corporate information address  saw mill river road ardsley ny  united states phone  fax  web url wwwacordacom from the web personal information education university of marburg md memberships board memberships riemser arzneimittel ag board member present cambridge neuroscience inc board member present isis pharmaceuticals inc board member former show more sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data burkhard blank  acorda therapeutics  inc  zoominfocom acorda appoints burkhard blank md as chief medical officer cmo  business wire acorda appoints burkhard blank md as chief medical officer cmo named to position after serving as interim cmo since january  july    am eastern daylight time ardsley nybusiness wireacorda therapeutics inc nasdaqacor today announced that burkhard blank md has assumed the role of chief medical officer cmo effective immediately dr blank was appointed as acorda’s interim cmo in january  and previously served as cmo for several biopharmaceutical companies including boehringer ingelheim “i am delighted that burkhard has joined acorda as our cmo” said ron cohen md president and ceo of acorda therapeutics “burkhard brings to acorda an impressive record of successful drug development and approved ndas this will benefit acorda’s entire pipeline including our latestage development programs cvt and tozadenant for parkinson’s disease dr blank’s primary responsibilities include setting strategy for and execution of development programs from clinical trials through regulatory filings oversight of postmarketing studies for approved products and management of the company’s medical affairs clinical operations regulatory affairs drug safety and biostatistics departments “acorda has a very exciting neurology pipeline with the potential to address significant needs in parkinson’s disease poststroke migraine and multiple sclerosis with three separate clinicalstage programs that may advance care for people with parkinson’s disease we are positioned as a leader in pd therapeutic development” said burkhard blank md chief medical officer of acorda “my top priorities are to focus on moving our latestage programs cvt and tozadenant for pd toward regulatory submissions and to advance oncedaily dalfampridine into phase  clinical trials in poststroke walking difficulty” dr blank has more than  years of industry experience holding senior leadership positions with responsibility for managing international clinical trial programs as well as heading regulatory affairs statistics drug safety and related departments as cmo of boehringer ingelheim dr blank oversaw the submission of five new drug applications ndas and had direct responsibility for all aspects of presenting at two us food and drug administration fda advisory committee meetings subsequently all five ndas received fda approval dr blank has also served as a strategic advisor to several biotechnology companies leading the submission process for multiple investigational new drug applications inds successfully developing protocols for clinical trial programs and overseeing communications with regulatory agencies dr blank received his medical degree from universitaet marburg germany dr blank has collaborated with acorda since  first as consultant to the company’s commercial and business development departments and then as interim cmo beginning in january  about acorda therapeutics founded in  acorda therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders including parkinson’s disease poststroke walking difficulties migraine and multiple sclerosis acorda markets three fdaapproved therapies including ampyra® dalfampridine extended release tablets  mg for more information please visit the company’s website at wwwacordacom forwardlooking statement this press release includes forwardlooking statements all statements other than statements of historical facts regarding managements expectations beliefs goals plans or prospects should be considered forwardlooking these statements are subject to risks and uncertainties that could cause actual results to differ materially including the ability to complete the biotie transaction on a timely basis the ability to realize the benefits anticipated from the biotie and civitas transactions among other reasons because acquired development programs are generally subject to all the risks inherent in the drug development process and our knowledge of the risks specifically relevant to acquired programs generally improves over time the ability to successfully integrate biotie’s operations and civitas’ operations respectively into our operations we may need to raise additional funds to finance our expanded operations and may not be able to do so on acceptable terms our ability to successfully market and sell ampyra dalfampridine extended release tablets  mg in the us third party payers including governmental agencies may not reimburse for the use of ampyra or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions the risk of unfavorable results from future studies of ampyra or from our other research and development programs including cvt or any other acquired or inlicensed programs we may not be able to complete development of obtain regulatory approval for or successfully market cvt any other products under development or the products that we will acquire when we complete the biotie transaction the occurrence of adverse safety events with our products delays in obtaining or failure to obtain and maintain regulatory approval of or to successfully market fampyra outside of the us and our dependence on our collaborator biogen in connection therewith competition failure to protect our intellectual property to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products and failure to comply with regulatory requirements could result in adverse action by regulatory agencies these and other risks are described in greater detail in our filings with the securities and exchange commission we may not actually achieve the goals or plans described in our forwardlooking statements and investors should not place undue reliance on these statements forwardlooking statements made in this press release are made only as of the date hereof and we disclaim any intent or obligation to update any forwardlooking statements as a result of developments occurring after the date of this press release contacts acorda therapeuticsjeff macdonald jmacdonaldacordacom contacts acorda therapeuticsjeff macdonald jmacdonaldacordacom search advanced news search advanced news search log in sign up burkhard blank  acorda therapeutics  email chief medical officer acordacom login  day free trial burkhard blank acorda therapeutics chief medical officer updated on  apr   export  saw mill river road ardsley ny  email format for acordacom direct phone not available type public employees    revenue  million   billion industry biotechhealthcarebiotechdrugs sic code   biological products except diagnostic biography burkhard blank is the current chief medical officer you can find burkhard blanks linkedin profile phone numbers wiki twitter and biography on acorda therapeuticss lead profile as well as acorda therapeutics email addresses with the acordacom domain format burkhard blanks email may or may not be inside the profile acorda therapeutics is situated in ardsley ny you can find their contact information on lead categorized under biotechdrugs some possible email formats for burkhard blank are bblankacordacom burkhardblankacordacom burkhardacordacom and burkhardblankacordacom if you sign up for our free trial you will see our emailacordacom addresses similar people burkhard bilger  other their staff writer is burkhard bilger their lead profile is categorized under the hotelsmotels industry if youre checking for the new yorker email addresses these are also available on lead with the newyorkercom email addresses and possibly burkhard bilgers email the new yorker is based in new york ny you can also get burkhard bilgers linkedin info twitter data phone numbers wiki and biography on their lead profile their contact information is filed under the hotelsmotels category some possible email formats for burkhard bilger are bbilgernewyorkercom burkhardbilgernewyorkercom burkhardnewyorkercom and burkhardbilgernewyorkercom if you sign up for our free trial you will see our emailnewyorkercom addresses burkhard blum a partnercopartner at bandwith ventures based in dublin  burkhard blum has a comprehensive profile on lead you can find the entry on bandwith ventures in our other category the company ceo is  there are email addresses on their profile and may include burkhard blum email format too you can also find other contact information like facebook phone numbers biography wiki and linkedin for burkhard blum some possible email formats for burkhard blum are bblumbandwvcom burkhardblumbandwvcom burkhardbandwvcom and burkhardblumbandwvcom if you sign up for our free trial you will see our emailbandwvcom addresses burkhard braun  technology their sr database engineer is burkhard braun their lead profile is categorized under the biotechdrugs industry if youre checking for qiagen inc email addresses these are also available on lead with the qiagencom email addresses and possibly burkhard brauns email qiagen inc is based in germantown md you can also get burkhard brauns linkedin info twitter data phone numbers wiki and biography on their lead profile their contact information is filed under the biotechdrugs category some possible email formats for burkhard braun are bbraunqiagencom burkhardbraunqiagencom burkhardqiagencom and burkhardbraunqiagencom if you sign up for our free trial you will see our emailqiagencom addresses similar employees jeff macdonald  executive jeff macdonald is part of acorda therapeutics an organization which has its main offices in ardsley ny jeff serves as the sr director corporate communications at acorda therapeutics if youre searching for acorda therapeutics email addresses you can also find those on their lead profile with the domain acordacom along with jeff macdonalds linkedin name twitter tweets wiki phone numbers and biographyacorda therapeuticss lead profile is categorized under the biotechdrugs industry some possible email formats for jeff macdonald are jmacdonaldacordacom jeffmacdonaldacordacom jeffacordacom and jeffmacdonaldacordacom if you sign up for our free trial you will see our emailacordacom addresses jonathan kuhn  sales  marketing acorda therapeuticss director of global  brand marketing is jonathan kuhn they are based in ardsley ny and you can find their lead profile filed under the biotechdrugs industry jonathan kuhns profile contains twitter phone numbers linkedin wiki and biography information and you can also find other acorda therapeutics contact information and email addresses on lead with the acordacom domain format some possible email formats for jonathan kuhn are jkuhnacordacom jonathankuhnacordacom jonathanacordacom and jonathankuhnacordacom if you sign up for our free trial you will see our emailacordacom addresses kevin drain  executive kevin drain is the current senior area business manager you can find kevin drains linkedin profile phone numbers wiki twitter and biography on acorda therapeuticss lead profile as well as acorda therapeutics email addresses with the acordacom domain format kevin drains email may or may not be inside the profile acorda therapeutics is situated in ardsley ny you can find their contact information on lead categorized under biotechdrugs some possible email formats for kevin drain are kdrainacordacom kevindrainacordacom kevinacordacom and kevindrainacordacom if you sign up for our free trial you will see our emailacordacom addresses people directory  burkhard blank acorda therapeutics inc  acorda appoints burkhard blank md as chief medical officer cmo toggle navigation menu privacy policy terms of use site map contact us  back investor news acorda appoints burkhard blank md as chief medical officer cmo  download this press release pdf named to position after serving as interim cmo since january  ardsley nybusiness wire acorda therapeutics inc nasdaqacor today announced that burkhard blank md has assumed the role of chief medical officer cmo effective immediately dr blank was appointed as acorda’s interim cmo in january  and previously served as cmo for several biopharmaceutical companies including boehringer ingelheim “i am delighted that burkhard has joined acorda as our cmo” said ron cohen md president and ceo of acorda therapeutics “burkhard brings to acorda an impressive record of successful drug development and approved ndas this will benefit acorda’s entire pipeline including our latestage development programs cvt and tozadenant for parkinson’s disease dr blank’s primary responsibilities include setting strategy for and execution of development programs from clinical trials through regulatory filings oversight of postmarketing studies for approved products and management of the company’s medical affairs clinical operations regulatory affairs drug safety and biostatistics departments “acorda has a very exciting neurology pipeline with the potential to address significant needs in parkinson’s disease poststroke migraine and multiple sclerosis with three separate clinicalstage programs that may advance care for people with parkinson’s disease we are positioned as a leader in pd therapeutic development” said burkhard blank md chief medical officer of acorda “my top priorities are to focus on moving our latestage programs cvt and tozadenant for pd toward regulatory submissions and to advance oncedaily dalfampridine into phase  clinical trials in poststroke walking difficulty” dr blank has more than  years of industry experience holding senior leadership positions with responsibility for managing international clinical trial programs as well as heading regulatory affairs statistics drug safety and related departments as cmo of boehringer ingelheim dr blank oversaw the submission of five new drug applications ndas and had direct responsibility for all aspects of presenting at two us food and drug administration fda advisory committee meetings subsequently all five ndas received fda approval dr blank has also served as a strategic advisor to several biotechnology companies leading the submission process for multiple investigational new drug applications inds successfully developing protocols for clinical trial programs and overseeing communications with regulatory agencies dr blank received his medical degree from universitaet marburg germany dr blank has collaborated with acorda since  first as consultant to the company’s commercial and business development departments and then as interim cmo beginning in january  about acorda therapeutics founded in  acorda therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders including parkinson’s disease poststroke walking difficulties migraine and multiple sclerosis acorda markets three fdaapproved therapies including ampyra® dalfampridine extended release tablets  mg for more information please visit the company’s website at wwwacordacom forwardlooking statement this press release includes forwardlooking statements all statements other than statements of historical facts regarding managements expectations beliefs goals plans or prospects should be considered forwardlooking these statements are subject to risks and uncertainties that could cause actual results to differ materially including the ability to complete the biotie transaction on a timely basis the ability to realize the benefits anticipated from the biotie and civitas transactions among other reasons because acquired development programs are generally subject to all the risks inherent in the drug development process and our knowledge of the risks specifically relevant to acquired programs generally improves over time the ability to successfully integrate biotie’s operations and civitas’ operations respectively into our operations we may need to raise additional funds to finance our expanded operations and may not be able to do so on acceptable terms our ability to successfully market and sell ampyra dalfampridine extended release tablets  mg in the us third party payers including governmental agencies may not reimburse for the use of ampyra or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions the risk of unfavorable results from future studies of ampyra or from our other research and development programs including cvt or any other acquired or inlicensed programs we may not be able to complete development of obtain regulatory approval for or successfully market cvt any other products under development or the products that we will acquire when we complete the biotie transaction the occurrence of adverse safety events with our products delays in obtaining or failure to obtain and maintain regulatory approval of or to successfully market fampyra outside of the us and our dependence on our collaborator biogen in connection therewith competition failure to protect our intellectual property to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products and failure to comply with regulatory requirements could result in adverse action by regulatory agencies these and other risks are described in greater detail in our filings with the securities and exchange commission we may not actually achieve the goals or plans described in our forwardlooking statements and investors should not place undue reliance on these statements forwardlooking statements made in this press release are made only as of the date hereof and we disclaim any intent or obligation to update any forwardlooking statements as a result of developments occurring after the date of this press release view source version on businesswirecom httpwwwbusinesswirecomnewshomeen source acorda therapeutics inc acorda therapeuticsjeff macdonald jmacdonaldacordacom stock quote acor common stock     volume  more july   quick links view our investor kit meet our leadership team board of directors contact us pipeline sec filings email alerts unsubscribe from email alerts email address  mailing lists  news releases alert sec alert events alert calendar alert   enter the code shown above  text size normal larger largest print about acorda message from our ceo company leadership management team board of directors partnering with acorda grant program scientific award contact us compliance for patients focus on therapies in the community resources policy on access to unapproved medicines products  research pipeline arcus® technology products ampyra® dalfampridine zanaflex capsules® tizanidine hcl qutenza® capsaicin  patch clinical trials research  development cvt tozadenant syn syn btt timolumab cvt rhigm investors corporate governance stock information investors events press releases financial information quarterly reports annual reports sec filings analysts investor resources investor kit email alerts faqs ir contact news  events in the news awards press releases company events social media careers working at acorda meet our employees benefits job openings application home  privacy policy  terms of use  site map  contact us  copyright  powered by q inc burkhard blank md executive profile  biography  bloomberg july    pm et biotechnology company overview of acorda therapeutics inc snapshotpeople  overviewboard memberscommittees executive profile burkhard blank mdchief medical officer acorda therapeutics incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationshipsas of fiscal year  background dr burkhard blank md has been the chief medical officer of acorda therapeutics inc since july   and served as its interim chief medical officer from january   to june   dr blank has been the chief medical officer at herantis pharma oyj since april  dr blank served as head of clinical development  regulatory affairs at mersana therapeutics inc dr blankhas more than  years of industry experience holding senior leadership positions  with responsibility for managing international clinical trial programs as well as heading regulatory affairs statistics drug safety and related departments dr blank served as senior vice president of medical and drug regulatory affairs of boehringer ingelheim pharmaceuticals inc a subsidiary of boehringer ingelheim corporation he served as global head for regulatory affairs at boehringer ingelheim from  to  thereafter chief medical officer at boehringer ingelheim us from  to  he served as the chief medical officer and executive vice president of altus pharmaceuticals inc from january  to march   senior vice president of medicine regulatory affairs and project management from june   to january  and also served as its senior vice president of development until january  from october  to june  dr blank served as senior vice president for medicine and drug regulatory affairs at boehringer ingelheim usa in this role he was responsible for clinical development medical affairs regulatory affairs and quality assurance as well as project management prior to his position he held a number of positions with increasing levels of responsibility at boehringers head office in ingelheim germany while at boehringer ingelheim usa he was responsible for a staff of  and an annual recruitment of  patients in the north and south america region of boehringer ingelheim usa he joined boehringer ingelheim gmbh in  and served as its head of international project management and drug regulatory affairs since  dr blank founded the international project management department at boehringer ingelheim gmbh he served as project leader for worldwide development of various programs at bi from  to  dr blank has been a director of cenes pharmaceuticals inc since july  he serves as a member of advisory board of riemser pharma gmbh he holds a medical degree and residency training in internal medicine from universitaet marburg germany and postdoctoral training at the immunology department of the childrens hospital in toronto he is qualified to practice in both the united states and canadaread full background corporate headquarters  saw mill river roadardsley new york united statesphone fax  board members memberships presentdirectorcenes pharmaceuticals inc education md philippsuniversität marburg other affiliations cenes pharmaceuticals incaltus pharmaceuticals incmersana therapeutics incboehringer ingelheim corporationboehringer ingelheim pharmaceuticals incriemser pharma gmbhphilippsuniversität marburgherantis pharma oyj annual compensation salarytotal annual compensation stocks options restricted stock awardsall other compensationunexercisable optionstotal number of options total compensation total annual cash compensationtotal short term compensationother long term compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationnamepositioncompanycompensationjames e brown dvmcofounder chief executive officer president and directordurect corporationkarthur joseph higgins ceo president  directordepomed incpaul m bisaro president ceo  directorimpax laboratories incstephen r davis jdchief executive officer president and directoracadia pharmaceuticals incmjohn anthony sedor chairman and chief executive officerpernix therapeutics holdings inckcompensation as of fiscal year  sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact acorda therapeutics inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close burghardt sporting goods  you cant beat burghardt  log in or create an account shop retail shop team spirit wear design rewards blog promo products team sports baseballaccessoriesapparelbaseball bagsbaseball batsbaseballsbasesbatting glovescapscatchers equipmentcoaching aidsfootweargloveshelmetspitching machineprotective gearscorebookstraining aidssoftballaccessoriesapparelbagsbatting glovescatchers equipmentcoaching aidsfootweargloveshelmetspitching machineprotective gearsoftball batssoftballstraining aidsbasketballaccessoriesapparelbasketball bagsbasketball unitsbasketballscoaching aidsfootwearprotective gearscorebookstraining aidsfield hockeyaccessoriesapparelcoaching aidsfield hockey bagsfield hockey ballsprotective gearstickstraining aidsfootballaccessoriesapparelcoaching aidsfootball bagsfootball glovesfootballsfootwearhelmetsprotective gearscorebooksshoulder padstraining aidslacrosseaccessoriesapparelcoaching aidscomplete sticksfootweargoalsheadshelmetslacrosse bagslacrosse ballsprotective gearscorebooksshaftstraining aidspickleballaccessoriesnetspaddlespickleballsrugbyaccessoriesapparelcoaching aidsprotective gearrugby bagsrugby ballstraining aidssocceraccessoriesapparelcoaching aidsfootweargoalie gearscorebooksshin guardssoccer bagssoccer ballstraining aidstennisaccessoriesapparelcoaching aidsracquetsscorebookstennis bagstraining aidstrack  fieldcross countryaccessoriesapparelbagscoaching aidsfootwearshot putdiscusbatonstraining aidsvolleyballaccessoriesapparelcoaching aidsfootwearprotective gearscorebookstraining aidsvolleyball bagsvolleyballswrestlingaccessoriesapparelcoaching aidsfootwearprotective geartraining aidswrestling bagsofficialsaccessoriesapparelfootwearprotective gearscorebooksindividual sports badmintonracquetsshuttle cocksdisc golfaccessoriesracquetballaccessoriesracquetballsswimmingaccessoriesgogglesswim capsswimweargolfaccessoriesapparelbagsclubsfootweargolf ballstraining aidsfootwear mensbaseballbasketballcross trainingfootballlacrosseofficialsrunningsandalssoccersoftballtrack  fieldcross countryvolleyballwrestlingwomensbasketballcheerleadingcross trainingfield hockeylacrosseofficialsrunningsandalssoccersoftballtrack  fieldcross countryvolleyballyouthbaseballbasketballcross trainingfootballrunningsandalssoccersoftballwrestlingaccessoriesfootwear careinsolesshoelacessocksapparel mensaccessoriesall compressioncold compressionjackets and vestspantsshirts and topsshortssweatshirts and hoodiesunderwearwomensaccessoriesall compressioncold compressionjackets and vestspantsshirts and topsshortsskirtsskortssweatshirts and hoodiesunderwearboysaccessoriesall compressioncold compressionjackets and vestspantsshirts and topsshortssweatshirts and hoodiesunderweargirlsaccessoriesall compressionjackets and vestpantsshirts and topsshortsskirtsskortssweatshirts and hoodiesunderwearaccessoriescapshatsheadbandswinterwristbandsfitness accessoriescountdown watchesfitness ballsfoam rollersjump ropesmatspedometersresistance bandsstopwatchesweight trainingcross fitness traininggloves and strapshand and body weightsmedicine ballspull uppush up barsweightssports medicineathletic trainingbraces and supportsphysical educationaccessoriesball bagsballscones  markersjump ropespumpsscoreboardsprotective gearapparelcupssupportersguardspadsmouthguardsgames outdoorrec roomdartstable tennisaccessories backpacks and duffel bagssunglassesmenwomenwater bottlesnoveltiesstadium chairs blankcustomizedpink products other you cant beat burghardt team spirit wearuniforms gift cards and e certificates deals             burghardt gift cards the perfect gift   give the perfect gift burghardt gift cards connect with us join the burghardt community share your team news and events recommend new products receive alerts on new arrivals hot products ripit sporting goods prob prototype ii bbcor adult baseball bat oz dropprice sale price  nike inc gl mojo double dozen golf ballsprice  burghardt repeat rewards tshirts for life go ahead reward yourself join repeat rewards today burghardt gift cards and ecertificates buy now check your burghardt ecertificate balance shop burghardt shop team spirit wear design rewards blog community company info homeaboutterms employment opportunitiescontactstore informationbsg online accountother informationsale itemsreturnexchange policy help help section brookfield location  fox point location  toll free  store hours mf  sat  sun  team sales mf  sat  sun pickups only connect with us bernhard  burkard product design  home bernhard  burkard en  de industrial design  development fields industrial designproduct developmentinnovation managementinterior designcorporate identity services design conceptswe develop design concepts for your needs it is our aim to present a wide range of possible optionsidea generationsometimes ideas may come while dreaming but mostly they are based on creative workflows and smart evaluation methods innovation managementonly realization makes an idea to an innovation we offer clever approaches and solutions to create or improve productsproduct developmentwe offer profound technological knowledge in construction and engineering we develop dcad models and working prototypesdesign consultingwe offer consulting services in conceptual creative and human centered design user interface designwe develop strategies for the interaction between user and machines in order to optimize usabilitycorporate designwe shape your corporate identity by offering concepts of brand value marketing ideas product design and communication strategiesredesign studywe redesign products in contemporary design at the same time we optimize usability material sourcing and production highend renderingsin the design process we create meaningful highend images to show details and materials close to reality these cgi renderings can also be used for packaging or advertising purposesprototypeswe create prototypes to check proportion feasibility and ergonomics design models can be used for presentations photo shoots or trade exhibitionsfactory sourcingwe are in contact with factories all over the world in a wellproved sourcing method we find the right partner for youindustry we develop concepts and ideas to enter industry  portfolio industrial designproduct designinterior designcorporate designredesign studyinnovation managementshowcaseall  and more  raclette oven lea  aroma diffuser plama  marble run d ballo  portable speaker oksana  coat hanger installations giraffe  floor lamp cablepig  cable reel curt  deck chair clients start upbrandsindustryglobal playerprivate clientsall about us the focus of bernhard  burkard design studio lies on innovative and creative industrial design that is highly esthetic and offers an appropriate resource management design starts with a call for change besides elaborate technical skills it needs curiosity and the will to face the world with open eyes beyond styling and optical dressing contemporary design as a process for products and communication will generate the additional benefit that leads to sustainable success for all users who we are contact bernhard burkard gmbh schützenstrasse  ch stetten sh switzerland phone     email  bitte javascript aktivieren um die emailadresse sichtbar zu machen  please activate javascript to see email address press  bitte javascript aktivieren um die emailadresse sichtbar zu machen  please activate javascript to see email address